Abstract
Advancements in understanding of the genetics, genomics, biochemistry and the pharmacology of cancer in human, have driven the current cancer chemotherapy to intently focus on development of target-based approaches rather than conventional approaches. From among the various targets identified, validated and inhibited at different hallmarks of cancer, protein tyrosine kinases (PTKs) have been exploited the most. Insulin receptors (IRs), insulin like growth factor receptors (IGF-1R) and their hybrid receptors belong to tyrosine kinase receptor (TKR) family, constitute a structural homology among them and generate a growth promoting IGF system on binding with either insulin, IGF-1 or IGF-2. The system induces the mitogenic effects through a torrent of cell signals produced as a result of cross talk with other growth promoting peptides and steroidal hormones, ultimately resulting in hijacking apoptosis and increasing cell proliferation and cell survival in cancer cells. Various strategies such as anti-IGF-1R antibodies, IGF-1 mimetic peptides, antisense strategies, IGF-1R specific peptide aptamers, targeted degradation of IGF-1R and expression of dominant negative IGF- 1R mutants have been explored to inhibit the IGF-1R signaling. However, targeting IGF-1R with small molecules has gained considerable attention in last few years due to their ease of synthesis, ease of optimization of absorption, distribution, metabolism, excretion and toxicity (ADMET) parameters, oral route of administration, lesser side effects and cost effectiveness. The present review provides a broad overview and discusses the highlights on discoveries, SAR studies and binding interactions of small molecules with either IGF-1R active or allosteric sites reported till date.
Keywords: Cancer, IGF-1R, IGF-1R inhibitors, IR, SAR, Tyrosine Kinases
Mini-Reviews in Medicinal Chemistry
Title:Recent Advancements in Small Molecule Inhibitors of Insulin–like Growth Factor-1 Receptor (IGF-1R) Tyrosine Kinase as Anticancer agents
Volume: 13 Issue: 5
Author(s): Arvind Negi, P. Ramarao and Raj Kumar
Affiliation:
Keywords: Cancer, IGF-1R, IGF-1R inhibitors, IR, SAR, Tyrosine Kinases
Abstract: Advancements in understanding of the genetics, genomics, biochemistry and the pharmacology of cancer in human, have driven the current cancer chemotherapy to intently focus on development of target-based approaches rather than conventional approaches. From among the various targets identified, validated and inhibited at different hallmarks of cancer, protein tyrosine kinases (PTKs) have been exploited the most. Insulin receptors (IRs), insulin like growth factor receptors (IGF-1R) and their hybrid receptors belong to tyrosine kinase receptor (TKR) family, constitute a structural homology among them and generate a growth promoting IGF system on binding with either insulin, IGF-1 or IGF-2. The system induces the mitogenic effects through a torrent of cell signals produced as a result of cross talk with other growth promoting peptides and steroidal hormones, ultimately resulting in hijacking apoptosis and increasing cell proliferation and cell survival in cancer cells. Various strategies such as anti-IGF-1R antibodies, IGF-1 mimetic peptides, antisense strategies, IGF-1R specific peptide aptamers, targeted degradation of IGF-1R and expression of dominant negative IGF- 1R mutants have been explored to inhibit the IGF-1R signaling. However, targeting IGF-1R with small molecules has gained considerable attention in last few years due to their ease of synthesis, ease of optimization of absorption, distribution, metabolism, excretion and toxicity (ADMET) parameters, oral route of administration, lesser side effects and cost effectiveness. The present review provides a broad overview and discusses the highlights on discoveries, SAR studies and binding interactions of small molecules with either IGF-1R active or allosteric sites reported till date.
Export Options
About this article
Cite this article as:
Negi Arvind, Ramarao P. and Kumar Raj, Recent Advancements in Small Molecule Inhibitors of Insulin–like Growth Factor-1 Receptor (IGF-1R) Tyrosine Kinase as Anticancer agents, Mini-Reviews in Medicinal Chemistry 2013; 13 (5) . https://dx.doi.org/10.2174/1389557511313050004
DOI https://dx.doi.org/10.2174/1389557511313050004 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Newer Approaches to the Discovery of Glitazones
Mini-Reviews in Organic Chemistry Cytoprotective Effects of 5 Benzophenones and a Xanthone from Hypericum annulatum in Models of Epirubicin-Induced Cytotoxicity: SARAnalysis and Mechanistic Investigations
Medicinal Chemistry The Role of Natural Products in the Ligand Deorphanization of TRP Channels
Current Pharmaceutical Design Effect of Cholinergic Stimulation in Early Alzheimers Disease - Functional Imaging During a Recognition Memory Task
Current Alzheimer Research Access-site Complications of the Transradial Approach: Rare But Still There
Current Cardiology Reviews Relevance of the Neuropeptide Y System in the Biology of Cancer Progression
Current Topics in Medicinal Chemistry Inhaled Corticosteroids in Asthmatic Children: Are They as Safe in Infants and Preschoolers as in Older Children? A Review
Current Drug Safety Metabolic and Cardiovascular Complications of Highly Active Antiretroviral Therapy for HIV Infection
Current HIV Research Carcinoma of the Lower Uterine Segment (LUS): Clinicopathological Characteristics and Association with Lynch Syndrome
Current Genomics Pulmonary Rehabilitation as Evaluated by Clinical Trials: An Overview
Reviews on Recent Clinical Trials Association between Statin Use and Poor Outcomes in COVID-19 Patients with Diabetes Mellitus: A Systematic Review
Current Diabetes Reviews Combination of Daidzein, Hemin and Bms182874 Halts the Progression of Diabetes-Induced Experimental Nephropathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Biology and Medicinal Chemistry Approaches Towards Various Apoptosis Inducers
Anti-Cancer Agents in Medicinal Chemistry Tau as a Therapeutic Target for Alzheimers Disease
Current Alzheimer Research Intra-uterine Growth Retardation as a Risk Factor of Postnatal Metabolic Disorders
Current Pharmaceutical Biotechnology Natural Product-Derived Small Molecule Activators of Hypoxia-Inducible Factor-1 (HIF-1)
Current Pharmaceutical Design Autophagy in Diabetic Retinopathy
Current Neuropharmacology Role of Biological Mediators of Tumor-Associated Macrophages in Breast Cancer Progression
Current Medicinal Chemistry Incretin-Based Therapy of Type 2 Diabetes Mellitus
Current Protein & Peptide Science Pyroptosis, Apoptosis, and Autophagy: Critical Players of Inflammation and Cell Demise in the Nervous System
Current Neurovascular Research